Sarcomere mutation negative hypertrophic cardiomyopathy is associated with ageing and obesity

Alejandro E de Feria,1 Andrew E Kott,2 Jason R Becker 3,4

ABSTRACT

Background Despite advances in our understanding of the genetic causes of hypertrophic cardiomyopathy (HCM), a large portion of this patient population do not carry sarcomere gene mutations when screened. It remains largely unknown why patients without sarcomere mutations develop asymmetric myocardial hypertrophy.

Methods We performed a retrospective analysis of probands with HCM who underwent genetic testing to determine if clinical phenotypes were different depending on sarcomere mutation status. A medical history, three generation family history and clinical phenotyping were performed on 127 probands with HCM. Genetic screening was performed using clinically available HCM genetic testing panels.

Results We found that probands with HCM with pathogenic sarcomere mutations were over three times more likely to have a family history of HCM (66% vs 17%, p<0.0001) and were diagnosed with HCM at a much younger age (32 vs 51 years old, p<0.0001). In contrast, probands with HCM without sarcomere mutations were significantly more obese (body surface area p=0.003, body mass index p=0.04 adjusted for age) and were more likely to present with left ventricular outflow tract obstruction (p=0.0483).

Conclusion Patients with sarcomere mutation negative HCM present at an older age and are more obese compared with patients with sarcomere mutation positive HCM. The role of ageing and obesity in asymmetric myocardial hypertrophy warrants further investigation.

INTRODUCTION

Hypertrophic cardiomyopathy (HCM), a disease typically characterised by abnormal asymmetric growth of the ventricular myocardium, is a common genetic cause of heart failure and sudden death. The prevalence of this condition is 1:500 and over the last 30 years there has been tremendous advancement in understanding the genetic underpinnings of this disorder.1–4 The genes implicated in HCM encode for a diverse array of proteins involved in the proper function of the cardiomyocyte sarcomere. Despite advances in understanding the genetics of this disease, the role of genetic testing in diagnosis and disease management continues to evolve.5

Importantly, 30%–60% of individuals with HCM do not carry a germline mutation when screened for sarcomere gene mutations.6

The identification of sarcomere gene mutations provided a foundation from which to study the mechanisms controlling cardiomyocyte hypertrophy and pathological myocardial remodelling. Through research spanning two decades, sarcomere gene mutations have been shown to cause perturbations in cardiomyocyte calcium handling, energy utilisation and sarcomere function.7–12 Importantly, selective methods to correct these abnormalities are actively being pursued as therapeutic strategies in patients with HCM. It remains unclear why patients with sarcomere mutation negative HCM develop myocardial hypertrophy and if different treatment strategies are required for this patient population.

In order to explore these questions, we comprehensively evaluated a cohort of
probands with HCM to identify similarities and differences between subjects with sarcomere mutation positive and negative HCM.

METHODS

Study population
The diagnosis of HCM in proband subjects (n=127) was defined using the following criteria: left ventricular hypertrophy with a maximal wall thickness (LVWTmax) ≥15 mm in the absence of aortic stenosis or hypertension. In subjects with a previous diagnosis of hypertension, evidence of asymmetric myocardial hypertrophy as defined by an interventricular septal thickness to left ventricular posterior wall thickness ratio >1.5 and LVWTmax ≥15 mm were required. All patients met with a physician and genetic counsellor and a three generation family history was documented. All subjects had a comprehensive physical examination, seated non-invasive blood pressure measurement, 12-lead ECG and Doppler echocardiography performed. Subjects were excluded from our analysis if they were not screened for sarcomere gene mutations or if they did not have complete diagnostic imaging to verify phenotype status.

Evaluation for sarcomere gene mutations
After appropriate genetic counselling and following patient consent, blood samples were obtained and sent to either Harvard Partners Laboratory of Molecular Medicine (Boston, Massachusetts, USA) or GeneDx (Gaithersburg, Maryland, USA) for sequencing and variant classification following American College of Medical Genetics-accepted guidelines.13 The following genes were sequenced in all subjects: ACTC1, MYBPC3, MYH7, MYL2, MYL3, TNNC1, TNNI3, TNNT2, TPM1, PRKAG2, LAMP2, GLA and TTR.14 Subjects who tested positive for pathogenic DNA variants in PRKAG2, LAMP2, GLA or TTR genes were excluded from analysis (n=2). Sarcomere gene variants classified as pathogenic, or likely pathogenic, were considered sarcomere gene mutations. All DNA variants classified as sarcomere mutations had a minor allele frequency <1×10⁻⁴.15

Echocardiographic imaging
Doppler echocardiography was performed on all subjects to assess LVWTmax, posterior or minimum left ventricular wall thickness, left ventricular function and the measurement of the peak left ventricular outflow tract (LVOT) gradient. LVOT obstruction was defined as peak gradient ≥30 mm Hg at rest or with exercise.

Statistical analysis
Mann-Whitney U test was used to assess continuous variables and Fisher’s exact test was used to assess categorical data. To adjust for age, we performed multiple regression analyses for each outcome individually with sarcomere mutation as the main predictor. Age was adjusted for by entering into the model with non-linear effects using the restricted cubic spline.

RESULTS

Family history of HCM is much less common in subjects with sarcomere mutation negative HCM
Of the 127 probands with HCM who underwent genetic screening for sarcomere gene mutations, 54% (n=68) tested positive for a pathogenic sarcomere mutation and 46% (n=59) tested negative for a sarcomere mutation (figure 1A and online supplemental table S1). The most common sarcomere genes with mutations were Myosin Binding Protein C3 (MYBPC3) and Myosin Heavy Chain 7 (MYH7) (figure 1B). Family history of HCM was over three times more common in subjects with sarcomere positive HCM compared with subjects with sarcomere negative HCM (p<0.0001, figure 2).

Patients with sarcomere mutation negative HCM present at an older age
Proband subjects with sarcomere positive HCM (n=68) were diagnosed 18 years earlier than probands with sarcomere negative HCM (n=59) (median 32.5 vs 51...
years old, p<0.0001, table 1). To control for an effect of family history on age of presentation, we performed a subgroup analysis of probands with only HCM with no family history of HCM (n=72). We found that probands with HCM with sarcomeric mutations but with no family history of HCM still presented 15 years earlier in life compared with probands with sarcomere negative HCM (median 37 vs 52 years old, p=0.0004). Therefore, probands with HCM with sarcomeric mutations presented at an earlier age regardless of family history. Both sarcomere positive and negative probands had a similar gender distribution. There was a slightly higher blood pressure in the probands with sarcomere negative HCM (~4 mm Hg), but when adjusted for age, this was not statistically different. Patients with sarcomere mutation negative HCM are more obese
In addition to the sarcomere negative probands presenting at an older age, these subjects were also more obese with larger body surface area (BSA) and body mass index (BMI) (table 1, age adjusted p=0.003 (BSA) and p=0.037 (BMI)).

Patients with sarcomere mutation negative HCM are more likely to have LVOT obstruction
The degree of asymmetric myocardial hypertrophy was less in the sarcomere mutation negative subjects and there was a trend to lower LVWTmax (table 2). When LVWTmax was indexed to BSA, there was a significant difference in the groups, reflective of the increased obesity

### Table 1 Baseline characteristics of proband subjects with HCM

<table>
<thead>
<tr>
<th></th>
<th>Sarcomere negative N=59</th>
<th>Sarcomere positive N=68</th>
<th>P value</th>
<th>Adjusted p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (years)</td>
<td>51.0 (39.5,59.0) 48±14.5</td>
<td>32.5 (16.8,46.3) 32±16.8</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Male (n)</td>
<td>38 (64%)</td>
<td>35 (51%)</td>
<td>0.15</td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mm Hg)</td>
<td>123 (112,137) 126.5±18.9</td>
<td>120 (107,128) 119±16.3</td>
<td>0.0253</td>
<td>0.398</td>
</tr>
<tr>
<td>Diastolic BP (mm Hg)</td>
<td>74 (67,81) 74.3±9.5</td>
<td>70 (62,78) 69.5±10.1</td>
<td>0.0242</td>
<td>0.196</td>
</tr>
<tr>
<td>Mean arterial pressure (mm Hg)</td>
<td>91.3 (83.3,99.2) 91.7±11.4</td>
<td>86.7 (78.3,93.3) 85.9±10.9</td>
<td>0.0163</td>
<td>0.232</td>
</tr>
<tr>
<td>BSA (m²)</td>
<td>2.14 (1.95,2.22) 2.09±0.25</td>
<td>1.91 (1.73,2.11) 1.90±0.33</td>
<td>0.0008</td>
<td>0.003</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.1 (27.7,34.9) 31.7±5</td>
<td>27.7 (23.3,33.7) 28±2.6</td>
<td>0.0026</td>
<td>0.037</td>
</tr>
</tbody>
</table>

All values expressed as median (25% percentile, 75% percentile) and mean±SD.

### Table 2 Myocardial hypertrophy and LVOT obstruction

<table>
<thead>
<tr>
<th></th>
<th>Sarcomere negative N=59</th>
<th>Sarcomere positive N=68</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVWTmax (mm)*</td>
<td>20 (18.22) 20.3±4.1</td>
<td>21 (18.27) 22.6±6.5</td>
<td>0.0686</td>
</tr>
<tr>
<td>Ratio LVWTmax:LWTTmin*</td>
<td>1.8 (1.57,2.1) 1.84±0.4</td>
<td>2.1 (1.66,3.0) 2.48±1.1</td>
<td>0.0011</td>
</tr>
<tr>
<td>LVWTmax/BSA (mm/mm²)*</td>
<td>9.6 (8.1,10.7) 9.9±2.3</td>
<td>10.9 (8.9,13.8) 12.3±4.8</td>
<td>0.0006</td>
</tr>
<tr>
<td>LVOT obstruction (%)†</td>
<td>32 (54)</td>
<td>24 (35)</td>
<td>0.0483</td>
</tr>
<tr>
<td>LVOT gradient (mm Hg)*</td>
<td>105 (43,141) 98.5±56.3</td>
<td>71 (43,91) 75±51.3</td>
<td>0.1050</td>
</tr>
</tbody>
</table>

*Values expressed as median (25% percentile, 75% percentile) and mean±SD.
†LVOT obstruction defined as LVOT gradient ≥30 mm Hg.

BSA, body surface area; LVOT, left ventricular outflow tract; LVWTmax, maximum left ventricular wall thickness; LVWTmin, minimum left ventricular wall thickness.
in sarcomere mutation negative subjects (table 2). LVOT obstruction (>30 mm Hg) was more prevalent in subjects with sarcomere mutation negative HCM (table 2).

DISCUSSION

There have been significant advances in our understanding of the genetic and molecular mechanisms regulating the development of HCM caused by sarcomere gene mutations. However, approximately half of all patients with HCM who undergo genetic screening do not have a sarcomere mutation and the cause of HCM in these individuals remains poorly defined. We compared HCM with and without sarcomere mutations and discovered that family history, age of diagnosis and obesity were quite different between the cohorts.

We found that probands with sarcomere mutation positive HCM were much more likely to have a family history of HCM. This correlation between family history and sarcomere mutation status in HCM has also been reported in HCM cohorts from other centres. It would be logical that since sarcomere mutations are associated with an autosomal dominant inheritance pattern that patients who harbour sarcomere mutations would be likely to have a family history of disease. However, the much lower rate of clinically affected family members in pedigrees of patients with sarcomere negative HCM suggests that the cause of asymmetric myocardial hypertrophy may be related to multiple different factors. One possibility is that these patients harbour germline mutations with very low penetrance that are not routinely screened for. Alternatively, the more likely explanation is that there are non-heritable somatic mutations or non-genetic environmental factors (or a combination of these two factors) that contribute to the development of asymmetric myocardial hypertrophy in these patients. Our results suggest that ageing and obesity may serve as potential non-genetic factors that contribute to disease development in patients with sarcomere negative HCM.

We found that subjects with sarcomere negative HCM were more obese compared with subjects with sarcomere positive HCM. Supporting our results is earlier work which showed that obesity is independently associated with an increase in left ventricular mass and may affect progression of heart failure in a cohort of subjects with non-genotyped HCM. More recently, Fumagalli et al again demonstrated that obesity is associated with long-term adverse events in HCM overall. Our results suggest that obesity and ageing may serve as potential non-genetic factors that contribute to disease development in patients with sarcomere negative HCM.

It remains to be elucidated how ageing influences the asymmetric myocardial hypertrophy seen in HCM.

LIMITATIONS

This was a cohort that was collected from a single centre and therefore may not be representative of patient populations in other geographical areas. However, it should be noted that the distribution of sarcomere gene mutations in our cohort was similar to datasets from other cohorts in the USA and Europe, with MYBPC3 and MYH7 gene mutations accounting for ~80% of the identified mutations in our probands with HCM. In addition, we found a similar trend with other studies with regard to patients with sarcomere positive HCM being more likely to have a family history of HCM.

CONCLUSION

A large portion of patients with HCM do not test positive for sarcomere gene mutations and the cause of disease in these individuals remains elusive. In our study, we found that patients with sarcomere negative HCM are much less likely to have a family history of HCM, present later in life and are more obese than patients with HCM with sarcomere gene mutations. It will be important to investigate how obesity and ageing influence asymmetric myocardial remodelling and if therapies targeting these pathways can benefit this patient population.

Acknowledgements The authors would like to acknowledge statistical support from Jianhui Zhu, UPMC Heart and Vascular Institute.

Contributors AE de Feria and Andrew E Kott designed the study, collected data, performed the analysis and wrote the manuscript.
Heart failure and cardiomyopathies

Funding NIH HL116803 and HL136824 to JRB.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The institutional review board at Vanderbilt University School of Medicine approved this study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is not-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Jason R Becker http://orcid.org/0000-0002-2107-8179

REFERENCES


